280 related articles for article (PubMed ID: 33140519)
21. Rural community pharmacist willingness to dispense Suboxone® - A secret shopper investigation in South-Central Appalachia.
Trull G; Major E; Harless C; Zule W; Ostrach B; Carpenter D
Explor Res Clin Soc Pharm; 2021 Dec; 4():100082. PubMed ID: 35479845
[TBL] [Abstract][Full Text] [Related]
22. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
[TBL] [Abstract][Full Text] [Related]
23. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
[TBL] [Abstract][Full Text] [Related]
24. Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences.
Wang K; Shafique S; Xiao D; Walter SM; Liu Y; Piamjariyakul U; Xie C
J Addict Dis; 2024; 42(1):33-44. PubMed ID: 36655851
[TBL] [Abstract][Full Text] [Related]
25. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
[TBL] [Abstract][Full Text] [Related]
26. Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation.
Sun T; Aroke H; Kogut S; Katenka N; Bratberg J; Buchanan A
Am J Drug Alcohol Abuse; 2022 Mar; 48(2):217-225. PubMed ID: 34780312
[No Abstract] [Full Text] [Related]
27. Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients.
Vicknasingam B; Dazali MN; Singh D; Schottenfeld RS; Chawarski MC
Drug Alcohol Depend; 2015 Jul; 152():164-9. PubMed ID: 25935736
[TBL] [Abstract][Full Text] [Related]
28. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
Vergara-Rodriguez P; Tozzi MJ; Botsko M; Nandi V; Altice F; Egan JE; O'Connor PG; Sullivan LE; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S62-7. PubMed ID: 21317596
[TBL] [Abstract][Full Text] [Related]
29. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation.
Randall A; Hull I; Martin SA
J Addict Med; 2023 Mar-Apr 01; 17(2):237-240. PubMed ID: 36149001
[TBL] [Abstract][Full Text] [Related]
30. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.
Nielsen S; Hillhouse M; Weiss RD; Mooney L; Sharpe Potter J; Lee J; Gourevitch MN; Ling W
Am J Addict; 2014; 23(4):343-8. PubMed ID: 24112096
[TBL] [Abstract][Full Text] [Related]
31. Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
McAnulty C; Bastien G; Eugenia Socias M; Bruneau J; Foll BL; Lim R; Brissette S; Ledjiar O; Marsan S; Talbot A; Jutras-Aswad D;
Drug Alcohol Depend; 2022 Oct; 239():109604. PubMed ID: 36037586
[TBL] [Abstract][Full Text] [Related]
32. Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.
Rudolph KE; Shulman M; Fishman M; Díaz I; Rotrosen J; Nunes EV
Addiction; 2022 Mar; 117(3):637-645. PubMed ID: 34338389
[TBL] [Abstract][Full Text] [Related]
33. Naloxone Accessibility Under the State Standing Order Across Mississippi.
Gravlee E; Ramachandran S; Cafer A; Holmes E; McGregor J; Jordan T; Rosenthal M
JAMA Netw Open; 2023 Jul; 6(7):e2321939. PubMed ID: 37410464
[TBL] [Abstract][Full Text] [Related]
34. Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.
Dalton K; Butt N
J Addict Nurs; 2019; 30(4):254-260. PubMed ID: 31800516
[TBL] [Abstract][Full Text] [Related]
35. Impact of pharmacist counseling to enhance the accessibility of naloxone nasal spray to patients in a community pharmacy setting.
Napoli K; Grant M; Remines J; Nadpara P; Goode JR
J Am Pharm Assoc (2003); 2021; 61(4S):S127-S134. PubMed ID: 33441280
[TBL] [Abstract][Full Text] [Related]
36. Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.
Jones JD; Manubay JM; Mogali S; Metz VE; Madera G; Martinez S; Mumtaz M; Comer SD
Drug Alcohol Depend; 2017 Oct; 179():362-369. PubMed ID: 28844013
[TBL] [Abstract][Full Text] [Related]
37. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
Worley MJ; Heinzerling KG; Shoptaw S; Ling W
Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
[TBL] [Abstract][Full Text] [Related]
38. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
[TBL] [Abstract][Full Text] [Related]
39. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers.
Comer SD; Collins ED
J Pharmacol Exp Ther; 2002 Nov; 303(2):695-703. PubMed ID: 12388653
[TBL] [Abstract][Full Text] [Related]
40. Changes in pain during buprenorphine maintenance treatment among patients with opioid use disorder and chronic pain.
Edwards KA; Vowles KE; McHugh RK; Venner KL; Witkiewitz K
J Consult Clin Psychol; 2022 Apr; 90(4):314-325. PubMed ID: 35007092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
